Pick a time period -
No more available filters You need to apply a filter before selecting newsroom

Use our filters to get your customized news. Save and subscribe to as many filters as you want, get the news that YOU are interested in right in your mailbox, RSS feed or in your personalized dashboard. Share your stories, news, multimedia and pressreleases and get a wider audience with news.cision.com.

Cantargia: abstract published for the oral presentation of antibody CAN04 phase I data at ASCO

Cantargia AB today announces that the abstract of the upcoming oral presentation of CAN04 phase I clinical data at the 2019 ASCO Annual Meeting is published on the conference website. The abstract reports available data on the 22 patients in the phase I trial based on the interim analysis performed in February 2019. These data show that the safety profile of CAN04 was good and that CAN04 treatment led to a decrease of the biomarkers IL-6 and CRP already after two weeks of therapy. Nine patients had stable disease as determined by irRC after eight weeks follow up. One patient with pancreatic

Alligator Bioscience: ADC-1013 clinical Phase I data to be presented at ASCO

Lund, Sweden, May 15, 2019 – Alligator Bioscience (Nasdaq Stockholm: ATORX), today announces that Janssen Biotech, Inc. (Janssen) will present data from a Phase I clinical study of ADC-1013 (JNJ-7107) at the upcoming ASCO Annual meeting held in Chicago on May 31- June 4. The study results show that side effects were generally mild and transient. The primary aim of the study was safety and to establish a recommended dose for Phase II. The study is still ongoing and has enrolled a total of 95 patients. The maximum tolerated dose has not yet been reached. Doses up to 1200 μg/kg i.v without

BerGenBio to present new NSCLC and AML clinical data and biomarker data from Phase II development programme with selective AXL inhibitor bemcentinib at ASCO 2019

· Two peer reviewed abstracts on Phase II clinical data with bemcentinib accepted for presentation at ASCO 2019 · Non-Small-Cell Lung Cancer (NSCLC) trial of bemcentinib in combination with pembrolizumab, data to be presented includes safety, response rates and overall survival · Acute Myeloid Leukaemia (AML) trial of bemcentinib in combination with low dose AraC chemotherapy or decitabine reported safety and rapid, durable complete response ratesBergen, Norway, 15 May 2019 – BerGenBio ASA (OSE: BGBIO) a clinical-stage biopharmaceutical company developing novel, selective AXL kinase

Oncopeptides Announces Melflufen Data Accepted for Presentation at 2019 ASCO Annual Meeting

Stockholm – May 15, 2019 – Oncopeptides AB (Nasdaq Stockholm: ONCO) announced today that data from its Phase 1/2 O-12-M1 study evaluating melflufen, a lipophilic peptide-conjugated alkylator belonging to the novel class of peptidase enhanced cytotoxics, in the treatment of relapsed/refractory multiple myeloma (RRMM) have been selected for poster presentation at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting taking place May 31 – June 4 in Chicago.The data offers an analysis of time to next treatment (TTNT) in patients with RRMM who were treated with melflufen and

Grant of share options to primary insiders in Atea ASA

On 15 May 2019, key employees in the Atea Group were granted share options in Atea ASA. The following primary insiders were granted options (in alphabetic order, by last name): Arunas Bartusevicius (Managing Director, Atea Baltics) has been granted 70,000 options vesting on December 15, 2022. Following the grant, Arunas Bartusevicius holds 260,000 options and 100,194 shares in Atea ASA. August Baumann (Senior Vice President, Atea ASA) has been granted 70,000 options vesting on December 15, 2022. Following the grant, August Baumann holds 280,000 options and 2,200 shares in Atea ASA.

Decisions taken by Altia’s Annual General Meeting 2019 and Altia’s Board of Directors

Altia Plc Stock Exchange Release 15 May 2019 at 8:45 pm EET  Decisions taken by Altia’s Annual General Meeting 2019 and Altia’s Board of Directors  Altia’s Annual General Meeting was held in Helsinki on 15 May 2019. The meeting adopted the financial statements and discharged the members of the Board of Directors and the CEO from liability for the financial year 2018.   Dividend payment  The meeting approved the proposal by the Board of Directors to pay a dividend of EUR 0.38 per share. The dividend will be paid on 24 May 2019 to a shareholder registered in the shareholders’

Demerger Flakk Composites AS

On 15.05.2019, the board of directors of Flakk Composites AS resolved to propose to its shareholders meeting that Flakk Composites AS shall demerger certain assets to two entities to be incorporated as part of the demerger, included in which are 25 000 000 shares in Hexagon Composites ASA. Flakk Composites AS is wholly owned by Flakk Gruppen AS, a company owned 98.7% by Knut Flakk, chairman of the board of Hexagon Composites ASA. Flakk Composites AS will change its name to Flakk Rollon AS as part of the demerger.After, and subject to, completion of the demerger Flakk Rollon AS will hold 4

Resolutions at GARO Aktiebolag’s Annual General Meeting 2019

At the Annual General Meeting of GARO Aktiebolag held on 15 May 2019, the following was resolvedElection of Board of Directors Stefan Jonsson (Chairman), Rickard Blomqvist, Susanna Hilleskog, Per Holmstedt and Lars-Åke Rydh were re-elected and Mari-Katharina Jonsson Kadowaki was elected as new member of the Board. Lars Svensson had declined re-election. Fees to the Board of Directors It was resolved that Board fees shall be paid by SEK 470,000 to the Chairman of the Board and SEK 210,000 to each of the Board members elected by the AGM. It was further resolved that fees for

Nuevolution AB (publ) announces timing for the release and webcast of the first quarter 2019 interim results

Stockholm, 15 May 2019 – Nuevolution AB (publ) (NUE.ST) announces today that it will report its interim report for the first quarter 2019 on Wednesday, 22 May 2019 after 18:00 CET. On Thursday, 23 May 2019 at 15:00 CET, the company’s executive management will host a conference call and webcast discussion of the results and provide an update on the pipeline programs and partnering activities. Access to the event can be obtained as follows: LIVE access on Thursday 23 May at 15:00 CET Telephone numbers: SE: +46 85 05 58 352 DK: +45 7815 0108 UK: +44 33 3300 9030 US: +1 833

SSM to focus on core business – intends to divest contracting operations and enter into a strategic partnership with Mecon

SSM Holding AB (publ), Sweden’s leading developer of smart, affordable homes, intends to carry out strategic measures to strengthen the company’s long-term competitiveness and profitability.  The company intends to focus its core operations on business and project development, sales and aftermarket and at the same time initiate a strategic partnership with Mecon Bygg AB, a contracting company specialized in cost-efficient design-build contracts for multi-dwelling housing. As a result, SSM and Mecon are discussing transferring SSM's construction operations to Mecon. SSM will now start

Report from ÅF Pöyry's Annual General Meeting 2019

Press release from ÅF Pöyry, May 15, 2019 For further information:Rickard Dahlgren, Associate General Counsel, +46 10 50 50 446On Wednesday May 15, 2019, ÅF Pöyry AB (publ)’s annual general meeting was held at the group’s headquarters in Solna, Sweden. Adoption of the Income Statement and the Balance SheetThe meeting adopted the income statements and balance sheets for the Group and the parent company for 2018. The members of the Board of Directors and the President were discharged from liability for the fiscal year 2018. DividendThe proposed dividend of SEK 5 per share was

Bulletin from the annual general meeting of Vicore Pharma Holding AB (publ)

The following resolutions were passed at the annual general meeting (the “AGM”) of Vicore Pharma Holding AB (publ) (”Vicore Pharma”) on 15 May 2019.Adoption of income statement and balance sheet for the financial year 2018 and discharge from liability The AGM resolved to adopt the income statement and the consolidated income statement for the financial year 2018 as well as the balance sheet and consolidated balance sheet as of 31 December 2018. The members of the board of directors and the managing director were discharged from liability for the financial year 2018. Allocation of

12 California Inns with Extraordinary Gardens

SACRAMENTO, CA [May 15, 2019]—In addition to their well-appointed rooms, delightful breakfasts, and uncompromising hospitality, bed and breakfast inns are just as often known for their vibrant gardens. The California Association of Boutique & Breakfast Inns (CABBI) has compiled a list of inns around the Golden State with a profusion of unique blooms and welcoming, intimate spaces. Known for drama, exuberance, and year-round color, the gardens at Half Moon Bay’s Mill Rose Inn  have been described as “extravagant” by the San Francisco Chronicle and as

Bulletin from Moberg Pharma’s AGM 2019

STOCKHOLM, May 15th, 2019. Moberg Pharma AB’s (“Company”) Annual General Meeting took place on Wednesday, May 15th, 2019 in the Company´s premises in Bromma, Sweden.Adoption of the income statements and the balance sheetsThe Annual General Meeting (the “Meeting”) approved the income statements and the balance sheets for the fiscal year 2018. The Meeting resolved, in accordance with the proposal of the Board of Directors, that no dividend should be paid for the fiscal year 2018. The Meeting discharged the Board members and the Chief Executive Officer from liability for the fiscal

Communiqué from annual general meeting in ChromoGenics AB (publ)

The annual general meeting in ChromoGenics AB (publ) was held on 15 May 2019 at Advokatfirman Lindahl’s offices on Vaksalagatan 10 in Uppsala whereby the shareholders resolved on the following main matters.Annual report and profit and loss statement The annual general meeting adopted the presented profit and loss statement and the balance sheet and resolved, in accordance with the board of directors’ proposal, to carry the accumulated loss forward in new account. No dividends will be paid for the financial year 2018. Discharge from liability The board of directors and the managing

Press release from Extraordinary General Meeting of Cereno Scientific AB (publ)

An Extraordinary General Meeting of Cereno Scientific AB (“Cereno”) was held today, 15 May 2019, at the offices of GU Ventures at Erik Dahlbergsgatan 11 in Gothenburg, Sweden. A summary of the resolutions made is presented below. All resolutions were unanimous.Resolution on changes to the Articles of Association The Meeting resolved, in accordance with the proposal from the Board of Directors, to adopt new Articles of Association with amended limits for share capital and the number of shares, as a result of which the Articles of Association have been amend as follows. Article 4 –

myTaste AB (publ): Mytaste Group change name to Speqta

myTaste AB (publ) (”Mytaste Group”), a digital media house that owns and operates a leading international advertising network as well as a number of digital products and services within performance-based marketing of e-commerce stores, today announces that the company, the group and its business areas change name to Speqta and that the products and services which previously been marketed under the names myTaste or Mytaste Group will now be marketed under the names Speqta or Speqta Group. At the Annual General Meeting, held on 13 May 2019, the shareholders resolved to change

Announcement from the Annual General Meeting of Eastnine AB (publ) on 15 May 2019

The Meeting adopted the income statements and balance sheets included in the Board of Directors’ Annual Report for the parent company and the Eastnine Group for the fiscal year 2018. The Meeting resolved to allocate this year’s result in accordance with the Board of Directors’ proposal, meaning a dividend to the shareholders corresponding to 2.30 SEK per share and that the remaining profits are carried forward. The dividend is distributed on two payment occasions of SEK 1.15 per share and dividend occasion. The first record date for the dividend is Friday 17 May 2019 and the second

Report from Annual General Meeting of SSM Holding AB (publ)

The shareholders of SSM Holding AB (publ) gathered in Stockholm, Sweden, on Wednesday May 15, 2019 for the Annual General Meeting.SSM’s Meeting approved the income statements and the balance sheets for the Company and the group and granted discharge from liability for the members of SSM’s board of directors and CEO for the 2018 financial year. The Meeting resolved to allocate the result in accordance with the proposal of the board of directors in the annual report. In accordance with the proposal by the nomination committee (i) Anders Janson, Bo Andersson, Per Berggren, Sheila Florell,

Annual General Meeting in Tethys Oil

The shareholders of Tethys Oil AB (publ) gathered in Stockholm, Sweden, Wednesday 15 May 2019 for the Annual General Meeting.The income statements and the balance sheets for the Company and the Group were approved and the Board of Directors and the Managing Director were discharged from liability for the financial year 2018. The Meeting resolved on a dividend for the financial year 2018 of SEK two (2) per share, amounting to a total of SEK 68,504,294 to be paid in two instalments of SEK one (1) per share each in May and November 2019. The record dates for the dividends are 17 May 2019

Share buy-back by Zalaris ASA

On 15 May 2019, Zalaris ASA purchased 1650 own shares on the Oslo Stock Exchange at an average price of NOK 24,8242. Following the purchase Zalaris ASA holds 267.562 own shares, representing ~1,33% of the total outstanding shares. The shares were purchased in accordance with the share buy-back programme announced 12 March 2019, available at www.newsweb.no. This information is subject to the disclosure requirements pursuant to section 5-12 of the Norwegian Securities Trading Act.

Bulletin from Bactiguard Holding AB’s (publ) Annual General Meeting

At Bactiguard Holding AB’s (publ) Annual General Meeting (AGM) on 15 May, 2019 the following resolutions were made:The AGM adopted the income statements and balance sheets for 2018 and decided that no dividend for the financial year 2018 will be paid. Retained earnings and the company's loss for the year will be carried forward. The Board of Directors and CEO were discharged from liability for the financial year 2018. An annual remuneration of SEK 400 000 will be paid to the chairman of the Board and SEK 200 000 to each of the other external directors, with the exception of Thomas von

Bulletin from the annual general meeting of Green Landscaping Holding AB (publ)

At the annual general meeting in Green Landscping Holding AB (publ) today 15 May 2019, the shareholders resolved upon the following:Adoption of income statement and balance sheet as well as consolidated income statement and consolidated balance sheetThe annual general meeting adopted the income statement and consolidated income statement as well as the balance sheet and the consolidated balance sheet for the financial year 2018. Resolution on allocation of the company’s profitsThe annual general meeting approved the proposal of the board of directors that the company’s accumulated

There are no items matching the current filter
There are no more items matching the current filter
Back to top